Doxorubicin Hydrochloride

Spécifications

25316-40-9Numéro CAS

246-818-3Numéro CE

(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochlorideNom IUPAC

C27H30ClNO11Formule chimique

580 g/molMasse molaire

Doxorubicin Hydrochloride; 25316-40-9; Doxorubicin HCl; ADRIAMYCIN HYDROCHLORIDE; Adriacin; Adriamycin PFS; Adriamycin RDF; ADRIAMYCIN, HYDROCHLORIDE; Adriablastina cs; DTXSID3030636; doxorubicin.HCl; hydroxydaunomycin hydrochloride; 82F2G7BL4E; Doxorubicini hydrochloridum; Doxorubicin citric acid salt; DTXCID1010636; Liposomal doxorubicin hydrochloride; DOXORUBICIN HYDROCHLORIDE LIPOSOME; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)-; FI 106; adriamycine; Farmiblastina; Adrimedac; Doxolem; Doxorubin; Urokit Doxo cell; Urokit Doxo-cell; DOXO cell; DOXO-cell; FI-106; NSC123127; RefChem:5781; DOXIL (LIPOSOMAL); Hydrochloride, Doxorubicin; Chloridrato de Doxorrubicina; doxorubicin hydrochloride, Liposomal; 14-Hydroxydaunorubicin Hydrochloride; Doxorubicin hydrochloride (liposomal); F.I 106; 3-Hydroxyacetyldaunorubicin Hydrochloride; (2S,4S)-4-(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-2,5,12-trihydroxy-2-hydroxyacetyl-7-methoxy-1,2,3,4-tetrahydrotetracene-6,11-dione monohydrochloride; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)-; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S-cis)-; L-Lyxo-hexopyranoside, 3b-glycol-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-, hydrochloride; Rubex; Hydroxydaunorubicin hydrochloride; Adriblastina; Doxil; Caelyx; MFCD00077757; Doxorubicin (hydrochloride); Adriblastin; ADM hydrochloride; Doxorubicin (Adriamycin) HCl; MLS001401460; (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride; SMR000058570; DSSTox_CID_10636; DSSTox_RID_80678; DSSTox_GSID_45111; Adrosal; Duxocin; Lipodox; MLS000028393; Lipo-Dox; FI 6804; (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, hydrochloride (1:1), (8S,10S)-; SR-01000003049; C27H30ClNO11; UNII-82F2G7BL4E; Resmycin; CCRIS 740; Doxorubicin hydrochloride [JAN]; icin Hydrochloride; Adriamycin (TN); Adriacin (TN); Prestwick_188; EINECS 246-818-3; Doxorubicin hydrochloride [USP:JAN]; Doxil (TN); Rubex (TN); CPD000058570; Adriblastina hydrochloride; Doxorubicine hydrochloride; ADRIAMYCIN [IARC]; Doxorubicin hydrochloride?; NCGC00163543-01; SCHEMBL3242; CAS-25316-40-9; Doxorubicin hydrochloride RS; Doxorubicin hydrochloride CRS; MLS000049969; MLS000049970; MLS000049971; MLS000070047; MLS000392861; MLS000392871; MLS000392881; MLS000392891; MLS000392901; MLS000759533; MLS001055359; CHEMBL359744; orb1310036; orb3141277; SCHEMBL29349501; SCHEMBL29567127; CHEBI:31522; GLXC-06425; HMS1569G18; HMS6018M19; KUC110341C; MSK001346A; EX-A1337; Tox21_110050; Tox21_112061; Tox21_202483; Adriamycin (Doxorubicin Hydrochloride; EBC-11150; HB4183; HY-15142R; s1208; AKOS007930231; AKOS015920241; Doxorubicin hydrochloride (JP18/USP); Tox21_110050_1; AD15377; CCG-100975; CS-1239; Doxorubicin (hydrochloride) (Standard); NC00225; DOXORUBICIN HYDROCHLORIDE [MART.]; DOXORUBICIN HYDROCHLORIDE [VANDF]; NCGC00014486-01; NCGC00024415-33; NCGC00024415-36; NCGC00260032-01; NCGC00263918-03; (8S,10S)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride; AD184265; AS-31687; BD164391; DOXORUBICIN HYDROCHLORIDE [USP-RS]; DOXORUBICIN HYDROCHLORIDE [WHO-DD]; DOXORUBICIN HYDROCHLORIDE [WHO-IP]; HY-15142; SY059508; KSC-230-184-1; DOXORUBICIN HYDROCHLORIDE [EMA EPAR]; Doxorubicin hydrochloride - Bio-X trade mark; NS00093622; DOX; D01275; DOXORUBICIN HYDROCHLORIDE [EP MONOGRAPH]; DOXORUBICIN HYDROCHLORIDE [ORANGE BOOK]; EN300-123444; DOXORUBICIN HYDROCHLORIDE [USP MONOGRAPH]; DOXORUBICIN HYDROCHLORIDE LIPOSOME [VANDF]; DOXORUBICINI HYDROCHLORIDUM [WHO-IP LATIN]; F021790; Doxorubicin hydrochloride, 10 mg/ml aqueous solution; Doxorubicin hydrochloride, 98.0-102.0% (HPLC); IMX-110 COMPONENT DOXORUBICIN HYDROCHLORIDE; LIPOSOMAL DOXORUBICIN HYDROCHLORIDE [WHO-DD]; SR-01000003049-5; Q27032359; SR-01000003049-10; Z1557399790; Doxorubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard; Doxorubicin hydrochloride, suitable for fluorescence, 98.0-102.0% (HPLC); Doxorubicin Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material; Doxorubicin hydrochloride, United States Pharmacopeia (USP) Reference Standard; (1S,3S)-3,5,12-Trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside--hydrogen chloride (1/1); (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dionehydrochloride; (8S,10S)-10-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride; (8S,10S)-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-8-GLYCOLOYL-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-5,12-NAPHTHACENEDIONE HYDROCHLORIDE; (8S,10S)-10-[[(2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-2-tetrahydropyranyl]oxy]-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione Hydrochloride; (8S,10S)-10-{[(2R,4S,5S,6S)-4-AMINO-5-HYDROXY-6-METHYLOXAN-2-YL]OXY}-6,8,11-TRIHYDROXY-8-(2-HYDROXYACETYL)-1-METHOXY-5,7,8,9,10,12-HEXAHYDROTETRACENE-5,12-DIONE HYDROCHLORIDE; 5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYLACETYL)-1-METHOXY-, HYDROCHLORIDE (8S-CIS)-; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)-; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxylacetyl)-1-methoxy-, hydrochloride (8S-cis)-; 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-|_-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, hydrochloride (1:1), (8S,10S)-Synonymes